Procyanidin C1 modulates microglia cellular iron homeostasis via targeting HuR/ACSL4 pathway and alleviates high-glucose-induced ferroptosis in diabetic retinopathy.
Investigating the potential role of the RNA-binding protein human antigen R (HuR) in mediating ferroptosis during DR progression, as well as the protective effects of Procyanidin C1 (PC1), demonstrated that PC1 significantly alleviated oxidative stress and ferroptosis in both diabetic mice and high-glucose-treated BV2s.
Abstract
Diabetic retinopathy (DR), one of the most prevalent microvascular complications of diabetes, is a vision-threatening ocular disease. Although ferroptosis has been implicated in DR development, research on its underlying mechanisms and targeted therapeutics remains limited. Procyanidins, a class of polyphenolic compounds, exhibit robust anti-inflammatory properties and regulatory effects on various pathological processes. Herein, we investigated the potential role of the RNA-binding protein human antigen R (HuR) in mediating ferroptosis during DR progression, as well as the protective effects of Procyanidin C1 (PC1). Streptozotocin-induced diabetic mice and high-glucose-exposed BV2 microglial cells (BV2s) were treated with PC1 to evaluate oxidative stress and the expression of ferroptosis markers. The interaction between HuR and ACSL4 was characterized using ribonucleoprotein (RNP) immunoprecipitation (IP) and mRNA stability assays. Our results demonstrated that PC1 significantly alleviated oxidative stress and ferroptosis in both diabetic mice and high-glucose-treated BV2s. Mechanistically, post-transcriptional regulation by HuR via stabilizing Acsl4 mRNA contributes to the acceleration of ferroptosis during DR progression. Ultimately, PC1 suppresses DR advancement by targeting the HuR-ACSL4 signaling axis, highlighting its potential as a therapeutic intervention.
The UCHL1/NRF2 axis may represent a therapeutic target in DR and co-immunoprecipitation and ubiquitination assays demonstrated that UCHL1 interacted with NRF2 and stabilized NRF2 by removing K48-linked polyubiquitin chains.
Sanhua Xu, Jun Huang, Yi-Cang Wang et al.· Biochemical Pharmacology· 0 citations
These findings identify CANA as a promising therapeutic candidate for DR, acting through TLR4/NF-κB/NLRP3-dependent modulation of microglial activation and inhibited the TLR4/NF-κB/NLRP3 pathway.
Tai Guo, Yue Liu, Mengxiao He et al.· Current Eye Research· 0 citations
Low-dose DFO effectively mitigates HG-induced ferroptosis and inflammatory responses in MGCs through the Nrf2/TXNRD1 signaling axis, providing a theoretical framework for developing novel therapeutic strategies in DR management.
Min Luo, Yi Zhang, Na Li et al.· International Journal of Oph...· 0 citations
Findings suggest that EGCG alleviates RPE damage associated with NF-κB p65-mediated ferroptosis, providing new insights into AMD pathogenesis and a promising therapeutic strategy.
Xiao-Yang Chen, Miao Han, Yi-Wen An et al.· Experimental Eye Research· 0 citations
Tet alleviates hypoxia-induced microglial M1 polarization and microglia-mediated photoreceptor cell injury, at least partly through modulation of NF-κB/p65 signaling, which identifies Tet as a candidate compound for further preclinical investigation in retinal neuroinflammation associated with DR.
Findings identify a novel circFBXO7-TFCP2 regulatory axis linking metabolic stress to endothelial ferroptosis, providing new insight into the molecular basis of diabetic vascular dysfunction.